Acute and long-Term treatment of late-Life major depressive disorder: Duloxetine versus placebo

American Journal of Geriatric Psychiatry

Volumn 22, Issue 1, 2014, Pages 34-45

  Robinson, Michael ^a   Oakes, Tina Myers ^a   Raskin, JoelLiu ^a   Liu, Peng ^b   Shoemaker, Scarlett ^a   Craig Nelson, J ^c  

^a Lilly USA   (United States)

^b ELI LILLY AND COMPANY   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Duloxetine; Elderly depression; Pain; Symptom severity

Indexed keywords

ALANINE AMINOTRANSFERASE; DULOXETINE; GLUCOSE; HEMOGLOBIN A1C; PLACEBO; ANTIDEPRESSANT AGENT; THIOPHENE DERIVATIVE;

ABNORMAL LABORATORY RESULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; BRIEF PAIN INVENTORY; CLINICAL ASSESSMENT TOOL; CLINICAL GLOBAL IMPRESSION SCALE; CONTROLLED STUDY; DIASTOLIC BLOOD PRESSURE; DOUBLE BLIND PROCEDURE; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG FATALITY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; ECG ABNORMALITY; FEMALE; FRANCE; GERIATRIC DEPRESSION SCALE; GERIATRIC PATIENT; GERONTOPSYCHIATRY; GLUCOSE BLOOD LEVEL; HAMILTON SCALE; HEMOGLOBIN BLOOD LEVEL; HUMAN; HYPERTENSION; LEUKOCYTE COUNT; LUNG EMBOLISM; MAJOR CLINICAL STUDY; MAJOR DEPRESSION; MALE; MEXICO; MULTICENTER STUDY; NUMERIC RATING SCALE; ORTHOSTATIC HYPOTENSION; OUTCOME ASSESSMENT; PAIN ASSESSMENT; PATIENT GLOBAL IMPRESSION OF IMPROVEMENT; PSYCHOPHARMACOTHERAPY; PUERTO RICO; PULSE RATE; RANDOMIZED CONTROLLED TRIAL; RATING SCALE; SUICIDAL IDEATION; SYSTOLIC BLOOD PRESSURE; TREATMENT DURATION; UNITED STATES; UNSPECIFIED SIDE EFFECT; VERY ELDERLY; WEIGHT GAIN; WEIGHT REDUCTION; CLINICAL TRIAL; COMPLICATION; DEPRESSIVE DISORDER, MAJOR; ONSET AGE; PAIN; PSYCHOLOGICAL RATING SCALE;

AGE OF ONSET; AGED; AGED, 80 AND OVER; ANTIDEPRESSIVE AGENTS; DEPRESSIVE DISORDER, MAJOR; DOUBLE-BLIND METHOD; FEMALE; HUMANS; MALE; PAIN; PSYCHIATRIC STATUS RATING SCALES; THIOPHENES;

EID: 84893342882     PISSN: 10647481     EISSN: 15457214     Source Type: Journal    
DOI: 10.1016/j.jagp.2013.01.019     Document Type: Article

References (33)

1. American Psychological Association: Psychology and aging: addressing mental health needs of older adults [APA Web site]. Available at: http://apa.org/topics/aging/index.aspx. Accessed October 11, 2010
2. Fiske A, Wetherell JL, Gatz M: Depression in older adults. Annu Rev Clin Psychol 2009; 5:363-389
3. Nelson JC, Delucchi K, Schneider LS: Efficacy of second generation antidepressants in late-life depression: a meta-analysis of the evidence. Am J Geriatr Psychiatry 2008; 16(7):558-567
4. Kok RM, Heeren TJ, Nolen WA: Continuing treatment of depression in the elderly: a systematic review and meta-analysis of double-blinded randomized controlled trials with antidepressants. Am J Geriatr Psychiatry 2011; 19(3):249-255
5. Eli Lilly and Company: Cymbalta (duloxetine hydrochloride) prescribing label [Cymbalta Web site]. November 8, 2010. Available at: http://www.cymbalta. com. Accessed November 19, 2010
6. Raskin J, Wiltse CG, Siegal A, et al: Efficacy of duloxetine on cognition, depression, and pain in elderly patients with major depressive disorder: an 8-week, double-blind, placebo-controlled trial. Am J Psychiatry 2007; 164(6):900-909
7. American Psychiatric Association: Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition Text Revision (DSM-IVTR). Washington, DC, American Psychiatric Association, 2000
8. Folstein MF, Folstein SE, McHugh PR: "Mini-mental state." A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 1975; 12(3):189-198
9. Montgomery SA, Åsberg M: A new depression scale designed to be sensitive to change. Br J Psychiatry 1979; 134:382-389
10. Maier W, Philipp M: Improving the assessment of severity of depressive states: a reduction of the Hamilton Depression Rating Scale. Pharmacopsychiatry 1985; 18:114-115
11. Yesavage JA, Brink TL, Rose TL, et al: Development and validation of a geriatric depression screening scale: a preliminary report. J Psychiatr Res 1982-1983; 17(1):37-49
12. Guy W: ECDEU Assessment Manual for Psychopharmacology, revised. Rockville, MD, National Institute of Mental Health, Psychopharmacology Research Branch, 1976; pp 217-222
13. National Institute of Mental Health: ECDEU Assessment Manualfor Psychopharmacology, revised. Rockville, MD, National Instituteof Mental Health, Psychopharmacology Research Branch, 1976; pp 313-331
14. Mundt J, Brannan S, DeBrota D, et al: Memory Enhanced Retrospective Evaluation of Treatment (MERET). Proceedings of the National Institutes of Health 43rd Annual Meeting, New Clinical Drug Evaluation unit, held in Boca Raton, FL. May 2003
15. Cleeland CS, Ryan KM: Pain assessment: global use of the BriefPain Inventory. Ann Acad Med Singapore 1994; 23(2):129-138
16. Lezak MD: Neuropsychological Assessment (Third Edition). New York, NY, Oxford University Press, 1995; pp 438-445
17. Rey A: L'examen psychologique dans les cas d'encephalopathie traumatique. Arch de Psychol (Geneve) 1941; 28:286-340
18. Weschler D: Wechsler Adult Intelligence Scale-Third Edition. San Antonio, TX, The Psychological Corporation, 1997
19. Neisser U: Visual search. Sci Am 1964; 210:94-102
20. Mohs RC, Knopman D, Petersen RC, et al: Development of cognitive instruments for use in clinical trials of antidementia drugs: additions to the Alzheimer's Disease Assessment Scale that broaden its scope. The Alzheimer's Disease Cooperative Study. Alzheimer Dis Assoc Disord 1997; 11(suppl 2):S13-S21
21. Reitan RM: The relation of the Trail Making Test to organic brain damage. J Consult Psychol 1955; 19(5):393-394
22. Reitan RM, Wolfson D: The Trail Making Test as an initial screening procedure for neuropsychological impairment in older children. Arch Clin Neuropsychol 2004; 19(2):281-288
23. Kupfer DJ: Achieving adequate outcomes in geriatric depression: standardized criteria for remission. J Clin Psychopharmacol 2005; 25(4, suppl 1):S24-S28
24. Robinson M, Ahl J, Meyers AL, et al: Management of painful symptoms with duloxetine: a review of the efficacy in pre-clinical and clinical studies. Current Drug Ther 2011; 6:121-136
25. Bair MJ, Robinson RL, Katon W, et al: Depression and pain comorbidity: a literature review. Arch Intern Med 2003; 163(20): 2433-2445
26. Arnow BA, Hunkeler EM, Blasey CM, et al: Comorbid depression,chronic pain, and disability in primary care. Psychosom Med2006; 68(2):262-268
27. Bair MJ, Robinson RL, Eckert GJ, et al: Impact of pain on depression treatment response in primary care. Psychosom Med 2004; 66(1):17-22
28. Brannan SK, Mallinckrodt CH, Brown EB, et al: Duloxetine 60 mg once-daily in the treatment of painful physical symptoms inpatients with major depressive disorder. J Psychiatr Res 2005; 39(1):43-53
29. Mallinckrodt CH, Prakash A, Andorn AC, et al: Duloxetine for thetreatment of major depressive disorder: a closer look at efficacy and safety data across the approved dose range. J Psychiatr Res 2006; 40(4):337-348
30. Pigott TA, Prakash A, Arnold LM, et al: Duloxetine versus escitalopramand placebo: an 8-month, double-blind trial in patients with major depressive disorder. Curr Med Res Opin 2007; 23(6): 1303-1318
31. Whitmyer VG, Dunner DL, Kornstein SG, et al: A comparison of initial duloxetine dosing strategies in patients with major depressive disorder. J Clin Psychiatry 2007; 68(12):1921-1930
32. Brecht S, Desaiah D, Marechal ES, et al: Efficacy and safety of duloxetine 60 mg and 120 mg daily in patients hospitalized for severe depression: a double-blind randomized trial [published online ahead of print September 21, 2010]. J Clin Psychiatry 2011; 72(8):1086-1094
33. Brunton S, Wang F, Edwards SB, et al: Profile of adverse events with duloxetine treatment: a pooled analysis of placebocontrolled studies. Drug Saf 2010; 33(5):393-407